Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin

Trial Profile

A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IONIS-GCGRRx (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2019 Results evaluating the safety and efficacy of IONIS-GCGRRx from three phase 2 (NCT01885260, NCT02583919, NCT02824003) published in the Diabetes Care.
    • 24 Jan 2015 Planned number of patients changed from 72 to 77.
    • 24 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top